Related Experiment Video
Updated: Jan 16, 2026

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
Published on: July 5, 2021
Bioactive components from Kaixin san alleviate bradyarrhythmia via modulation of the calcium signaling pathway:
Yongyong Ren1, Peilin Wang1, Feng Yang1
1College of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an 712046, China.
Abstract:
Kaixin San (KXS), a traditional Chinese medicine formula, has shown therapeutic potential in treating bradyarrhythmia (BA), yet its active constituents and pharmacological mechanisms remain insufficiently defined. In this study, an integrated approach combining UPLC-Q-TOF/MS, network pharmacology, molecular docking, and experimental validation was employed to investigate the bioactive compounds and potential mechanisms of KXS. A total of 23 representative compounds were identified, including saponins, flavonoids, phenylpropanoids, organic acids, and lignans. Network pharmacology analysis revealed calcium signaling as a key pathway implicated in the anti-arrhythmic effect of KXS, with CACNA1C and CAMKIIδ predicted as major targets. Molecular docking and dynamics simulation confirmed strong binding affinity between KXS compounds and these core proteins. In a propranolol-induced BA rat model, KXS significantly improved cardiac conduction, modulated heart rate, and attenuated myocardial injury. Further experimental results confirmed that KXS downregulated the expression of CACNA1C and CAMKIIδ in myocardial tissue, suggesting its role in regulating intracellular calcium homeostasis. In conclusion, KXS alleviates bradyarrhythmia in rats, potentially by modulating calcium signaling pathways. This study highlights the multi-component and multi-target nature of KXS and provides a scientific basis for its application in BA treatment.
More Related Videos
08:11Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers